GYRE news & sentiment — GYRE THERAPEUTICS, INC.

MAY 8·Stock TitanMed

Gyre Therapeutics (GYRE) EVP details multiple stock option grants

Gyre Therapeutics' EVP and General Manager, Jialiang Wang, has reported initial holdings of multiple stock options for the company's common stock, as detailed in a recent Form 3 filing. The filing outlines various grants with different exercise prices and expiration dates, indicating a structured long-term equity incentive for Wang. Some options are fully vested, while others vest over time, contingent on continued service to the company.

MAY 8·Stock Titan

Gyre Therapeutics (GYRE) CSO discloses new Series B stake

Gyre Therapeutics' Chief Scientific Officer, Xiong Yue, has reported his initial ownership of 2,376,500 shares of Series B Preferred Stock following the merger of a Gyre subsidiary with Cullgen Inc. These shares are convertible into common stock at a 5:1 ratio after stockholder approval and are subject to a beneficial ownership limitation. The merger, effective May 4, 2026, resulted in Cullgen becoming a wholly-owned subsidiary of Gyre Therapeutics.

MAY 8·Stock Titan

Gyre Therapeutics (GYRE) GC holds option for 47,530 shares

Gyre Therapeutics (GYRE) General Counsel and Corporate Secretary, Joshua Benjamin Bergmann, has reported his initial ownership of a stock option for 47,530 shares of common stock. The option has an exercise price of $8.09 per share and expires on February 27, 2036. Vesting will occur in stages, with one-quarter on June 16, 2026, and the remainder monthly over the following three years, contingent on his continued employment.

$GYRE

Gyre Therapeutics (GYRE) EVP details multiple stock option grants

Gyre Therapeutics (GYRE) CSO discloses new Series B stake

Gyre Therapeutics (GYRE) GC holds option for 47,530 shares

News on $GYRE